Search results
Results from the WOW.Com Content Network
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes: to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. [2] when already being treated with metformin and saxagliptin and dapagliflozin. [2]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases ...
The SGLT2 inhibitor dapagliflozin has been indicated for the treatment of type 2 diabetes since 2012. ... an adjunct to insulin in patients with type 1 diabetes with a body-mass index (BMI) of 27 ...
Some of the most common pregnancy-related complications or conditions include gestational diabetes, infections, or severe nausea or vomiting. Another common condition that is frequently monitored ...
In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes: to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. [3] when already being treated with saxagliptin and dapagliflozin. [3]
President Joe Biden signed the Social Security Fairness Act into law Sunday afternoon, marking what is expected to be one of the last major pieces of legislation of his presidency. Prior to ...
It contains dapagliflozin, as propanediol monohydrate, a SGLT-2 inhibitor; and sitagliptin, as phosphate monohydrate, a DPP-4 inhibitor. [1] It is taken by mouth . [ 1 ]